A study on the blood samples derived from 15 AML patients and the electrophoretic mobility shift assay (EMSA) detected that malignant AML stem cells have NF-κB binding activity not seen in normal stem cells. This evidence concerns the gene NFKB1 and acute myeloid leukemia.